BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2022 2:23:07 PM | Browse: 591 | Download: 1136
 |
Received |
|
2021-09-06 17:40 |
|
Peer-Review Started |
|
2021-09-06 17:42 |
|
First Decision by Editorial Office Director |
|
2021-12-04 22:12 |
|
Return for Revision |
|
2021-12-04 22:12 |
|
Revised |
|
2021-12-05 10:00 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-09 06:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-10 16:32 |
|
Articles in Press |
|
2022-02-10 16:32 |
|
Edit the Manuscript by Language Editor |
|
2022-01-17 03:27 |
|
Typeset the Manuscript |
|
2022-02-23 08:47 |
|
Publish the Manuscript Online |
|
2022-03-15 14:23 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Almurtada Razok, Fateen Ata, Sara Mohamed Ibrahim Ahmed and Dabia Hamad S H Al Mohanadi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fateen Ata, BSc, MBBS, MD, Doctor, Doctor, Department of Internal Medicine, Hamad Medical Corporation, Al Rayyan Street, Bin Omran Area, Al Rayyan, Doha 3050, Qatar. docfateenata@gmail.com |
| Key Words |
Euglycemic diabetic ketoacidosis; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus; Empagliflozin |
| Core Tip |
With a steady surge in the prescription of sodium-glucose co-transporter 2 inhibitors (SGLT2-i) in medical conditions including type 2 diabetes mellitus (DM), type 1 DM, and heart failure, there are increasingly reported cases of euglycemic diabetic ketoacidosis (EDKA) with their use. EDKA in the context of SGLT2-i use is reported in various patients with different precipitating factors, some even with no inciting event. One of the rarely reported inciting events is stroke. Another aspect of SGLT2-i induced EDKA which remains relatively less understood is the time of initiation of the drug to the development of EDKA. In our patient, severe EDKA developed within 4 d of empagliflozin initiation, necessitating intensive care and discontinuation of empagliflozin, resulting in complete recovery regarding the EDKA. |
| Publish Date |
2022-03-15 14:23 |
| Citation |
Razok A, Ata F, Ahmed SMI, Al Mohanadi DHSH. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World J Diabetes 2022; 13(3): 272-274 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i3/272.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i3.272 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
